Drug Search Results
More Filters [+]

Lumiracoxib

Alternative Names: lumiracoxib
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: COX2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | India | New Zealand | Norway | Peru | Portugal | Slovenia | Sweden | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lumiracoxib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hypertension|Osteoarthritis|Pain Unspecified|Acute Pain|Musculoskeletal Pain|Healthy Volunteers

Phase 3: Osteoarthritis, Knee|Arthritis, Rheumatoid|Osteoarthritis, Hip|Osteoarthritis|Pain Unspecified

Phase 2: Arthralgia|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PEMEX-805415-00-2

P2

Terminated

Kidney Failure, Chronic|Arthralgia

2012-11-01

ND

P4

Completed

Unknown

2010-10-16

2005-005949-19

P3

Completed

Pain Unspecified

2006-12-15

2005-002772-14

P3

Completed

Osteoarthritis, Hip

2006-10-13

Recent News Events